At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 750 enrolled
Drug / intervention
CervarixTM +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) 580299 Vaccine in Healthy Chinese Female Subjects
In Brief
A Phase 3 clinical trial evaluating CervarixTM and Control for Infections, Papillomavirus. Completed, enrolled 750 participants across 1 site.
Detailed Summary
This study is designed to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine in pre-teen and adolescent female subjects aged 9 - 17 years. One group of subjects will receive the HPV vaccine and the other group will receive the control.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Papillomavirus
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2009
Enrollment StartOct 2009
Primary CompletionDec 2010
TodayJul 2026
First PostedOct 16, 2009
Enrollment StartOct 24, 2009
Primary CompletionDec 8, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.7 years ago
Interventions
CervarixTMbiological
Subjects will receive three doses of the Cervarix vaccine intramuscularly according to a 0, 1, 6-month schedule.
Controlother
Subjects will receive three doses of control intramuscularly according to a 0, 1, 6-month schedule.